Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 433 (TSXV: $KHRN.V) (TSX: $VIVO.TO) (OTC: $BBRW) (CSE: $IMCC.C)
Delta, Kelowna, BC, June 24, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/06241KHRN-VIVO-BBRW-IMCC.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announced the completed installation of a state-of-the-art 2,600 panel solar park that will generate electricity to power the Company's production facility in Doima, Colombia.
Developed with ReFeel, a leading Italian renewable Company with more than 80 MW installed in Europe and Latin America, Khiron's solar park is expected to generate up to 700 kWh through a photovoltaic (PV) system that comprises 2,618 installed solar panels. With the construction of the PV system, Khiron can self-generate up to 40% of the energy it needs for day-to-day facility operations and is expected to reduce CO2 emissions by 570 tons a year.
"Installation of the solar park at our Doima production facility brings Khiron exponential efficiencies, allowing us to significantly reduce operational energy costs and benefit from tax reductions, as we actively commit to deploying sustainability initiatives across our operations," comments Khiron CEO and Director Alvaro Torres. "We're proud to take actions aimed at sharply reducing greenhouse gas emissions and making this contribution to help counter the global environmental challenge."
The solar park project delivered direct employment to a team of 20 personnel in the local Doima community and provided access to globally recognized solar energy technical training in PV systems and renewable energy installations, enhancing the teams future participation in projects of the same type, at a regional and national level. "We are continuing to support the Doima community, improving resource and waste management in the area as part of our company-wide sustainability program," continues, Mr. Torres.
VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) and its subsidiaries have entered into both a product supply agreement and a clinic services agreement with Medical Cannabis by Shoppers™.
Under the terms of the supply agreement, the Company's licensed producers will offer a broad portfolio of Canna Farms™ and Beacon Medical™ branded medical cannabis products through the Medical Cannabis by Shoppers™ online sales platform, including its latest 2.0 offerings such as chocolates and extracts. VIVO-branded products will be accessible to Medical Cannabis by Shoppers™ patients across Canada.
"We have a six-year track record of cultivating and producing high-quality, medical-grade cannabis and are thrilled to partner with Shoppers Drug Mart Inc." said Barry Fishman, CEO of VIVO. "VIVO is extremely committed to the medical cannabis market. We are pleased to be able to leverage the insights learned from over 100,000 patient visits to our Harvest Medicine clinics and telemedicine platform. As we continue to invest in product development to expand our medical cannabis product line and satisfy unmet patient needs, we are excited by the prospect of introducing our novel future offerings to Medical Cannabis by Shoppers™ patients."
Under the terms of the clinic services agreement, the Company's subsidiary, Harvest Medicine, will provide cannabis education services to patients who are appropriate candidates for cannabinoid-based products available from Medical Cannabis by Shoppers™ and provide consulting services to its Cannabis Care team.
"As a leading clinic network dedicated to advancing medical cannabis patient outcomes through quality education, the team of health care practitioners at Harvest Medicine look forward to developing a collaborative interdisciplinary approach to medical cannabis care with Medical Cannabis by Shoppers™," commented Carole Chan, President of Harvest Medicine.
BrewBilt Manufacturing Inc. (OTC: BBRW) announced that the Beer-Industry giants are turning to CANNA-BEER processing in an effort to boost sales. As the laws continue to evolve, canna-beer, as part of the larger cannabis-infused beverage category, presents unique opportunities for seasoned and new users alike. More than just another way to get high, THC-infused beers offers a consistent, predictable, and responsible way to engage with cannabis.
CEO Jef Lewis stated, “We just received $1,050,000 in new orders, brewery and cannabis, in the past 48 hours. Statistical trends for 2020 indicated that quality was the most important factor when choosing an alcohol brand, so while consumers may not be drinking as frequently, when they do drink, they’re opting for quality over quantity or mindful drinking. 58% of Beer-Industry insiders state that quality beer and equipment is the new trend for 2020. BrewBilt has the highest reputation for quality equipment for cannabis and brewery systems. The future of our revenue model is based upon “ghost-breweries” where there is a huge demand for contract brewing and packaging, 68% of activity on the platform this year has come from people looking for contract brewing capacity. The white label market was valued at $100B in 2020 across all sectors. 32% of tender requests on the platform are for white label.”
Lewis further stated, “The future of BrewBilt is vibrant and aggressive as we meet quality demands in our industries. This means stabilization and a re-energized core of more successful breweries. Additionally, as we’ve already seen, the rise of cannabis and sobriety will play a role on the further impact of the beer category. The continued maturation of the category is going to force owners and leadership to get more organized, prepared, and professional. BrewBilt is on that forefront as growing demand for beers that are high in flavor and food compatibility, but lower in calories: fruit-infused sour beers and low-cal IPAs are two categories we believe will grow strong for many years to come. Our customers have come to trust our manufacturing processes and quality, and are going to continue demanding the latest new products. Their taste profiles will evolve over the next decade and we’ll see companies in our space evolve with our customers. For BrewBilt the next 10 years should be about making sure beer is America’s beverage of choice.”
IM Cannabis Corp. (CSE:IMCC), one of the world's pioneering medical cannabis companies with operations in Israel and across Europe, announced today that a recent peer-reviewed study conducted by Professor Dedi Meiri at the Technion – Israeli Institute of Technology ("Technion") investigating the associations between phytocannabinoid treatment and migraine frequency, found that medical cannabis results in long-term reduction of migraine frequency in over 60% of treated patients1. The study also found that medical cannabis is associated with less disability and lower antimigraine medication intake. Furthermore, Technion's research indicated that two strains used in the study (IMC's London and Tel-Aviv strains) were found to be specifically effective.
"At IMC, we have high conviction that the development of evidence-based research in medical cannabis will lead to a new generation of medical products to treat a variety of indications and illnesses over the long-term. We will continue to partner with visionaries and leading researchers such as Professor Dedi Meiri and Technion to advance research and development of medical cannabis as it aligns strongly with our vision of leadership in global medical cannabis," said Oren Shuster, CEO of IMC. "The results of this study follow our announcement last week of a binding term sheet with MGC Pharmaceuticals Ltd. to distribute CannEpil® in Israel for the treatment of refractory epilepsy. As we continue to develop relationships with innovators in research and development, we plan to use our global distribution network to bring a range of high-quality medical cannabis products to patients across the world."
Professor Dedi Meiri, commented, "In the past five years, my lab, together with the main growers in Israel, have been running the Israeli database project. As part of this project, we have been testing the associations between phytocannabinoid treatment and migraine frequency. In this work we observed that 89% of the respondents reported lower current migraine disability and lower negative impact, and lower rates of opioid and triptan consumption. Moreover, we were able to demonstrate that the respondents consumed cannabis strains with higher doses of the phytocannabinoid ms_373_15c and lower doses of the phytocannabinoid ms_331_18d. Two of the most impactful strains in the study were IMC branded strains, Tel-Aviv and London."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411